Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hardikkumar Jetani"'
Autor:
Pedro Romero, Andre Kunert, Hardikkumar Jetani, Katarzyna Franciszkiewicz, David Vlerick, Aleksandra Nowicka, Robert Y Igarashi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/7490abba5edc40e48765b49046654d54
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
Autor:
Andoni Garitano-Trojaola, Ana Sancho, Ralph Götz, Patrick Eiring, Susanne Walz, Hardikkumar Jetani, Jesus Gil-Pulido, Matteo Claudio Da Via, Eva Teufel, Nadine Rhodes, Larissa Haertle, Estibaliz Arellano-Viera, Raoul Tibes, Andreas Rosenwald, Leo Rasche, Michael Hudecek, Markus Sauer, Jürgen Groll, Hermann Einsele, Sabrina Kraus, Martin K. Kortüm
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Garitano-Trojaola et al. used a combination of human acute myeloid leukemia (AML) cell lines and primary samples to show that RAC1-dependent actin cytoskeleton remodeling through BCL2 family plays a key role in resistance to the FLT3 inhibitor, Midos
Externí odkaz:
https://doaj.org/article/97fe6acc0451456bbe96d2d7eec2c3f6
Autor:
Silke Frenz, Ana Yeguas, Judit Rial Saborido, Simone Thomas, Sabrina Kraus, Almudena Navarro-Bailón, Marius Maucher, Katrin Mestermann, Markus Sauer, Halvard Bonig, Christina Verbruggen, Hardikkumar Jetani, Hermann Einsele, Razieh Monjezi, Michael Hudecek, Marcos González, Maik Luu, Dimitrios Mougiakakos, María Belén Vidriales
Publikováno v:
Blood
Digital.CSIC. Repositorio Institucional del CSIC
instname
Digital.CSIC. Repositorio Institucional del CSIC
instname
Acute myeloid leukemia (AML) is an attractive entity for the development of chimeric antigen receptor (CAR) T-cell immunotherapy because AML blasts are susceptible to T-cell–mediated elimination. Here, we introduce sialic acid–binding immunoglobu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f106d114c68b766ffc0cb1c4540c2cb
http://hdl.handle.net/10261/262144
http://hdl.handle.net/10261/262144
Autor:
Halvard Bonig, Julian Rydzek, Thomas Nerreter, Wolfgang Herr, Irene García-Cadenas, Javier Briones Meijide, Hardikkumar Jetani, Michael Hudecek, Simone Thomas, Hermann Einsele, Jordi Sierra
Publikováno v:
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8(+) and CD4(+) T-cells expressing a FLT3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04106152bc03f312eff04d2702c65968
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3625
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3625
Autor:
Hardikkumar, Jetani, Irene, Garcia-Cadenas, Thomas, Nerreter, Simone, Thomas, Julian, Rydzek, Javier Briones, Meijide, Halvard, Bonig, Wolfgang, Herr, Jordi, Sierra, Hermann, Einsele, Michael, Hudecek
Publikováno v:
Leukemia. 32(5)
FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed on normal hematopoietic stem and progenitor cells (HSC) and retained on malignant blasts in acute myeloid leukemia (AML). We engineered CD8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2e5d08851461012bfee054ac9a8122db
https://pubmed.ncbi.nlm.nih.gov/29472720
https://pubmed.ncbi.nlm.nih.gov/29472720
Autor:
Sabrina Kraus, Markus Sauer, Raoul Tibes, Martin Kortüm, Andoni Garitano-Trojaola, Hermann Einsele, Leo Rasche, Hardikkumar Jetani, Nadine Rodhes, Ralph Goetz, Cornelia Vogt, Larissa Haertle, Susanne Walz, Jürgen Groll, Michael Hudecek, Ana Sancho, Matteo DaVia, Andreas Rosenwald, Silvia Nerreter, Johannes Duell, Eva Teufel
Publikováno v:
Blood. 134:1277-1277
Introduction Acute Myeloid Leukemia (AML) is a genetically heterogeneous disease characterized by clonal expansion of immature myeloid progenitor cells in the bone marrow (BM). Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approxim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1ffe8988032afc32bcbf3406b919af8
https://doi.org/10.1182/blood-2019-129762
https://doi.org/10.1182/blood-2019-129762
Autor:
Irene García-Cadenas, Markus Sauer, Halvard Bonig, Jorge Sierra, Hermann Einsele, Hardikkumar Jetani, Ralph Goetz, Michael Hudecek, Thomas Nerreter
Publikováno v:
Blood. 132:903-903
Background: FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein uniformly expressed on leukemic blasts in acute myeloid leukemia (AML), and driver of leukemia-genesis in FLT3-ITD+ (Internal tandem duplication) AML. There is an increasing bod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec741257e3ee8a39fd67727331ecf8b3
https://doi.org/10.1182/blood-2018-99-118171
https://doi.org/10.1182/blood-2018-99-118171
Autor:
Julia Beckmann, Herrmann Einsele, Hardikkumar Jetani, Sophia Danhof, Sabrina Prommersberger, Thomas Nerreter, Razieh Monjezi, Michael Hudecek
Publikováno v:
Current Research in Translational Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::620eb695483868aee788f75ef2e1e1e8